Katherine Heath

Dr. Katherine Heath

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
BSBryony Simmons
Bryony Simmons
JSJawaad Saleem
Jawaad Saleem
KHKatherine Heath
Katherine Heath
GCGraham S. Cooke
Graham S. Cooke
AHAndrew Hill
Andrew Hill
Background. Achievement of a sustained virologic response (SVR) after treatment for Hepatitis C infection is associated with improved outcomes. This meta-analysis aimed to determine the impact of SVR on long-term mortality risk compared with nonresponders in a range of populations. Methods. An electronic search identified all studies assessing all-cause mortality in SVR and non-SVR patients. Eligible articles were stratified into general, cirrhotic, and populations coinfected with human immunodeficiency virus. The adjusted hazard ratio (95% confidence interval [CI]) for mortality in patients achieving SVR vs non-SVR, and pooled estimates for the 5-year mortality in each group were calculated. Results. 31 studies (n = 33 360) were identified as suitable for inclusion. Median follow-up time was 5.4 years (interquartile range, 4.9–7.5) across all studies. The adjusted hazard ratio of mortality for patients achieving SVR vs non-SVR was 0.50 (95% CI, .37–.67) in the general population, 0.26 (95% CI, .18–.74) in the cirrhotic group, and 0.21 (.10–.45) in the coinfected group. The pooled 5-year mortality rates were significantly lower for patients achieving SVR compared with non-SVR in all 3 populations. Conclusions. The results suggest that there is a significant survival benefit of achieving an SVR compared with unsuccessful treatment in a range of populations infected with hepatitis C virus.

9 June 2021 in AIDS
Verified
Journal Article
Open access
KHKatherine Heath
Katherine Heath
JLJacob Levi
Jacob Levi
AHAndrew Hill
Andrew Hill
Background: The Joint United Nations Programme on HIV/AIDS aims for HIV testing, treatment and viral suppression rates to be 95%--95%--95% by 2025. Patented drug prices remain a barrier to HIV treatment. Generic alternatives are being produced and exported from countries without patent barriers at a fraction of the cost. Methods: We collated export records of active pharmaceutical ingredient for HIV drugs to estimate the minimum costs of production. Using epidemiological data describing national HIV epidemics, we calculated the cost to treat 164 countries at 95%--95%-95%. Using weighted log-linear regression models, we estimated the mother-to-child transmissions (MTCTs), HIV-related deaths and new HIV infections preventable every year by increased treatment. Findings: We estimated that TDF/3TC/DTG could be produced for $59 per person per year. At this price, the 164 countries in our analysis could be treated at 95%--95%--95% for $2 billion a year, preventing 66 308 MTCTs, 241 811 HIV-related deaths and 631 398 new HIV infections every year. In comparison, global expenditure on HIV pharmaceuticals in 2019 was $28 billion. Interpretation: At $2 billion/year, the 164 countries in our analysis could be treated for the price of 4 weeks of current global sales. Global access to generic alternatives could reduce expenditure and improve clinical outcomes.

15 February 2024 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
KHKatherine Heath
Katherine Heath
AHAndrew Hill
Andrew Hill

1 March 2022
Verified
Journal Article
Open access
KHKatherine Heath
Katherine Heath
MAMonica Alonso
Monica Alonso
GAGloria Aguilar
Gloria Aguilar
TSTania Samudio
Tania Samudio
EKEline Korenromp
Eline Korenromp
MTMelanie Taylor
Melanie Taylor
In Paraguay, incomplete surveillance data resulted in the burden of congenital syphilis being underestimated, which, in turn, led to missed opportunities for infant diagnosis and treatment. The prevalence of congenital syphilis, as defined by the World Health Organization (WHO), was estimated for Paraguay using the WHO congenital syphilis estimation tool. This tool was also used to monitor progress towards the elimination of mother-to-child transmission of syphilis. The burden of syphilis in Paraguay has historically been high: its prevalence in pregnant women was estimated to be 3% in 2018. The incidence rate of congenital syphilis estimated using the WHO tool was around nine times the reported prevalence. Subsequently, Paraguay: (i) provided training to improve diagnosis and case reporting; (ii) strengthened information systems for case monitoring and reporting; and (iii) procured additional rapid dual HIV–syphilis and rapid plasma reagin tests to increase syphilis testing capacity. In addition, the Ministry of Health prepared a new national plan for eliminating mother-to-child transmission of syphilis, with clear monitoring milestones. Health-care providers’ reporting and surveillance procedures for congenital syphilis may not adequately reflect national and international case definitions. Use of the WHO congenital syphilis estimation tool in Paraguay drew attention to congenital syphilis as a national public health problem and highlighted the importance of comprehensive national surveillance systems and accurate data. Ongoing use of the WHO tool can track progress towards the elimination of mother-to-child transmission of syphilis by helping improve syphilis service coverage and national surveillance.

28 January 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
KHKatherine Heath
Katherine Heath
AAAimee Altermatt
Aimee Altermatt
FSFreya Saich
Freya Saich
APAlisa Pedrana
Alisa Pedrana
SFStephanie Fletcher-Lartey
Stephanie Fletcher-Lartey
MHMargaret Hellard
Margaret Hellard
Background: High vaccine uptake requires strong public support, acceptance, and willingness. Methods: A longitudinal cohort study gathered survey data every four weeks between 1 October 2020 and 9 November 2021 in Victoria, Australia. Data were analysed for 686 participants aged 18 years and older. Results: Vaccine intention in our cohort increased from 60% in October 2020 to 99% in November 2021. Vaccine intention increased in all demographics, but longitudinal trends in vaccine intention differed by age, employment as a healthcare worker, presence of children in the household, and highest qualification attained. Acceptance of vaccine mandates increased from 50% in October 2020 to 71% in November 2021. Acceptance of vaccine mandates increased in all age groups except 18–25 years; acceptance also varied by gender and highest qualification attained. The main reasons for not intending to be vaccinated included safety concerns, including blood clots, and vaccine efficacy. Conclusion: COVID-19 vaccination campaigns should be informed by understanding of the sociodemographic drivers of vaccine acceptance to enable socially and culturally relevant guidance and ensure equitable vaccine coverage. Vaccination policies should be applied judiciously to avoid polarisation.

18 September 2025 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
KHKatherine Heath
Katherine Heath
LALincoln Muniz Alves
Lincoln Muniz Alves
MBMichael B. Bonsall
Michael B. Bonsall
Background: Climate change and urban expansion pose significant challenges to controlling Aedes aegypti mosquito populations, a primary vector of arboviruses such as dengue, Zika, and chikungunya. This study aims assess how climate and anthropogenic factors will jointly shape Ae. aegypti densities in Brazil, which is crucial to forecasting transmission risks and informing public health strategies. Methods: This study combined a biologically informed, stage-structured delay-differential equation model with climate and anthropogenic data. Climate projections from the Coupled Model Intercomparison Project Phase 6 under different Shared Socioeconomic Pathways (SSPs) were used to forecast future climate scenarios from 2024 to 2080. Boosted Regression Trees integrated anthropogenic factors like urbanisation, population growth, and urban accessibility. Model outputs were validated with entomological surveillance data, and the basic reproductive number for dengue fever was used to assess changes in disease transmission potential. Findings: Our findings predicted that Ae. aegypti mosquito density will increase nationally, but unevenly, exceeding thermal limits in North Brazil while rising substantially in the South and Southeast. Increases in density were particularly pronounced under high greenhouse gas emission scenario SSP5-8.5 (up to 92% in the Southeast). These trends were projected to elevate the transmission potential for dengue fever, with Southeast Brazil facing the biggest increases due to mosquito population growth outpacing human population expansion. Validation against historical data confirmed model robustness. Interpretation: By directly linking mosquito abundance to SSP-specific emissions trajectories, our results show that climate mitigation can markedly reduce disease risk. Shifting from SSP5-8.5 to SSP1-2.6 could cut projected mosquito density increases from 31% to 11% nationally by 2080. The model’s spatial granularity and integration of local administrative boundaries support its utility for national and sub-national health planning. Addressing compounded risks in vulnerable peri-urban and rural populations will require coordinated interventions that span climate policy, vector control, and health equity.